Current trends in the management of anaemia in solid tumours and haematological malignancies

Current Opinion in Supportive and Palliative Care

Volumn 10, Issue 2, 2016, Pages 189-194

  Van Eeden, Ronwyn ^a   Rapoport, Bernardo L ^a  

^a Medical Oncology   (South Africa)

Author keywords

anaemia; cancer; cancer related fatigue; erythropoiesis stimulating agents; iron therapy

Indexed keywords

ANTIANEMIC AGENT; HEMOGLOBIN;

ANEMIA; COMPLICATION; ERYTHROCYTE TRANSFUSION; HEMATOLOGIC DISEASE; HUMAN; NEOPLASM; PATHOPHYSIOLOGY; QUALITY OF LIFE;

ANEMIA; ERYTHROCYTE TRANSFUSION; HEMATINICS; HEMATOLOGIC NEOPLASMS; HEMOGLOBINS; HUMANS; NEOPLASMS; QUALITY OF LIFE;

EID: 84966440912     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0000000000000209     Document Type: Review

References (33)

1. Calabrich A, Katz A. Management of anemia in cancer patients. Future Oncol 2011; 7: 507-517
2. Schrijvers D, De Samblanx H, Roila F; ESMO Guidelines Working Group. Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use. Ann Oncol 2010; 21: v244-v247
3. Cella D. The effects of anemia and anemia treatment on the quality of life of people with cancer. Oncology (Williston Park) 2002; 16 (9 Suppl 10): 125-132
4. Bohlius J, Weingart O, Trelle S, et al. Cancer-related anemia and recombinant human erythropoietin-an updated overview. Nat Clin Pract Oncol 2006; 3: 152-164
5. Ludwig H, Van Belle S, Barrett-Lee P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence and treatment of anaemia in cancer patients. Eur J Cancer 2004; 40: 2293-2306
6. Lee P, Peng H, Gelbart T, et al. Regulation of hepcidin transcription by interleukin-1 and interleukin-6. Proc Natl Acad Sci U S A 2005; 102: 1906-1910
7. Alvarez-Hernaéndez X, Liceéaga J, McKay IC, et al. Induction of hypoferremia and modulation of macrophage iron metabolism by tumor necrosis factor. Lab Invest 1989; 61: 319-322
8. Ludwiczek S, Aigner E, Theurl I, et al. Cytokine-mediated regulation of iron transport in human monocytic cells. Blood 2003; 101: 4148-4154
9. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005; 352: 1011-1023
10. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997; 34 (3 Suppl 2): 13-19
11. Alexander S, Minton O, Stone PC. Evaluation of screening instruments for cancer-related fatigue syndrome in breast cancer survivors. J Clin Oncol 2009; 27: 1197-1201
12. Caro JJ1, Salas M, Ward A, et al. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001; 91: 2214-2221
13. Schrier SL, Steensma DP, Loprinzi CL. Role of erythropoiesis-stimulating agents in the treatment of anaemia in patients with cancer, UpToDate. Available at: http://www.uptodate.com/contents/search?search=anemia& x=0& y=0. [Accessed 6 January, 2016
14. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Cancer and Chemotherapy Induced Anemia. Version 2.2016. National Comprehensive Cancer Network. Available at: http://www.nccn.org. [Accessed 6 January, 2016
15. Schrijvers D. Management of anemia in cancer patients: transfusions. Oncologist 2011; 16: 12-18
16. Littlewood TJ, Nortier J, Rapoport B, et al. Epoetin (corrects anemia and improves quality of life in patients with hematologic malignancies receiving nonplatinum chemotherapy. Hematol Oncol 2003; 21: 169-180
17. Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo controlled, randomised phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2001; 94: 1211-1220
18. Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006; 98: 708-714
19. Glaspy JA. The development of erythropoietic agents in oncology. ExpertOpin Emerg Drugs 2005; 10: 553-567
20. Rizzo JD, Somerfield MR, Hagerty KL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. Blood 2008; 111: 25-41
21. Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008; 299: 914-924
22. Leyland-Jones B; BEST Investigators and Study Group. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003; 4: 459-460
23. Untch M, von Minckwitz G, Konecny GE, et al. Arbeitsgemeinschaft Gynä-kologische Onkologie PREPARE investigators. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer: outcome on prognosis. Ann Oncol 2011; 22: 1999-2006
24. Henke M, Laszig R, Rübe C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003; 362: 1255-1260
25. Overgaard J, Hoff C, Sand Hansen H, et al. Randomized study of the importance of novel erythropoiesis stimulating protein (Aranesp) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC): the Danish Head and Neck Cancer Group DAHANCA 10. Eur J Cancer Suppl 2007; 5: 7-7
26. Bohlius J, Schmidlin K, Brillant C, et al. Recombinant human erythropoiesisstimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009; 373: 1532-1542
27. Tonelli M, Hemmelgarn B, Reiman T, et al. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. CMAJ 2009; 180: E62-E71
28. Glaspy J, Crawford J, Vansteenkiste J, et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer 2010; 102: 301-315
29. Aapro MS, Link H. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist 2008; 13 (Suppl 3): 33-36
30. Baribeault D, Auerbach M. Iron replacement therapy in cancer-related anemia. Am J Health Syst Pharm 2011; 68 (10 Suppl 1): S4-S14
31. Henry DH, Dahl NV, Auerbach M, et al. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 2007; 12: 231-242
32. Hedenus M, Birgegård G, Näsman P, et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia 2007; 21: 627-632
33. Bastit L, Vandebroek A, Altintas S, et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapyinduced anemia. J Clin Oncol 2008; 26: 1611-1618